Vero Biotech Report issue

For profit Phase 3
Founded: Cocoa FL United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2010
NCT01092559
First Marketed Drug
2019
nitric oxide (inomax)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

VERO BIOTECH | VERO BIOTECH INC

Active Ingredients

Marketed Drugs (1)

nitric oxide (inomax) (2019)

Drugs in Phase 3 Trials (1)

nitric oxide (inomax) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 3)

Fibrosis (Phase 2)

Hypertension (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1